KR100836971B1 - 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도 - Google Patents

맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도 Download PDF

Info

Publication number
KR100836971B1
KR100836971B1 KR1020057005463A KR20057005463A KR100836971B1 KR 100836971 B1 KR100836971 B1 KR 100836971B1 KR 1020057005463 A KR1020057005463 A KR 1020057005463A KR 20057005463 A KR20057005463 A KR 20057005463A KR 100836971 B1 KR100836971 B1 KR 100836971B1
Authority
KR
South Korea
Prior art keywords
rapamycin
formula
compound
rejection
vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057005463A
Other languages
English (en)
Korean (ko)
Other versions
KR20050038656A (ko
Inventor
발터 슐레르
헨드릭 슈르만
기스베르트 벡크벡커
한스-귄터 제르베스
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100836971(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority claimed from KR1019980707662A external-priority patent/KR100616020B1/ko
Publication of KR20050038656A publication Critical patent/KR20050038656A/ko
Application granted granted Critical
Publication of KR100836971B1 publication Critical patent/KR100836971B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020057005463A 1996-03-27 1997-03-26 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도 Expired - Lifetime KR100836971B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds
GB9606452.2 1996-03-27
KR1019980707662A KR100616020B1 (ko) 1996-03-27 1997-03-26 맥관장애및이종이식술에서의라파마이신유도체의용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1019980707662A Division KR100616020B1 (ko) 1996-03-27 1997-03-26 맥관장애및이종이식술에서의라파마이신유도체의용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077008212A Division KR20070083654A (ko) 1996-03-27 1997-03-26 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도

Publications (2)

Publication Number Publication Date
KR20050038656A KR20050038656A (ko) 2005-04-27
KR100836971B1 true KR100836971B1 (ko) 2008-06-10

Family

ID=10791127

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020057005463A Expired - Lifetime KR100836971B1 (ko) 1996-03-27 1997-03-26 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도
KR1020077008212A Withdrawn KR20070083654A (ko) 1996-03-27 1997-03-26 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077008212A Withdrawn KR20070083654A (ko) 1996-03-27 1997-03-26 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도

Country Status (29)

Country Link
US (5) US6384046B1 (enExample)
EP (3) EP2008657B1 (enExample)
JP (2) JP2000507226A (enExample)
KR (2) KR100836971B1 (enExample)
CN (1) CN1124135C (enExample)
AT (1) ATE224194T1 (enExample)
AU (1) AU716514B2 (enExample)
BR (1) BR9708358A (enExample)
CA (1) CA2247275C (enExample)
CY (1) CY2404B1 (enExample)
CZ (1) CZ292483B6 (enExample)
DE (1) DE69715611T2 (enExample)
DK (2) DK0893996T3 (enExample)
ES (2) ES2184078T3 (enExample)
GB (1) GB9606452D0 (enExample)
HU (1) HU226422B1 (enExample)
ID (1) ID17195A (enExample)
IL (1) IL125812A (enExample)
MY (1) MY117798A (enExample)
NO (1) NO316667B1 (enExample)
NZ (1) NZ331463A (enExample)
PL (1) PL187732B1 (enExample)
PT (2) PT893996E (enExample)
RU (1) RU2214247C2 (enExample)
SI (1) SI2008657T1 (enExample)
SK (1) SK284343B6 (enExample)
TR (1) TR199801919T2 (enExample)
WO (1) WO1997035575A1 (enExample)
ZA (1) ZA972719B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ATE222502T1 (de) 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
ATE474590T1 (de) 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
IL151501A0 (en) 2000-03-15 2003-04-10 Orbus Medical Technologies Inc Coating that promotes endothelial cell adherence
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
DE60124285T3 (de) 2000-09-29 2011-03-17 Cordis Corp., Miami Lakes Beschichtete medizinische geräte
EP2762140B1 (en) * 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20050255111A1 (en) * 2002-02-22 2005-11-17 Olle Korsgren Use of an inhibitor or antagonist against tissue factor
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CN1655738A (zh) * 2002-05-20 2005-08-17 奥勃斯医学技术股份有限公司 可植入的药物洗脱医疗装置
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
TW200605910A (en) * 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1838288A4 (en) * 2004-12-20 2010-08-04 Ariad Pharma Inc THERAPEUTIC MATERIALS AND METHODS
US20070185150A1 (en) 2005-11-14 2007-08-09 Bedrosian Camille L Therapeutic methods
US20080317814A1 (en) * 2005-11-17 2008-12-25 Access Plus Co., Ltd. Tube for Connecting Marteriovenous and Interposition for Medical Operation
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
CN101557814B (zh) 2006-09-13 2015-05-20 万能医药公司 大环内酯化合物及它们的使用方法
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
CN103480047B (zh) 2007-11-14 2015-02-18 生物传感器国际集团有限公司 自动化涂覆设备和方法
US8921642B2 (en) * 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
US20100086579A1 (en) * 2008-10-03 2010-04-08 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8366763B2 (en) 2009-07-02 2013-02-05 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
UA104738C2 (ru) 2011-05-18 2014-03-11 Олег Миколайович Лазаренко Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
BR112016006378A2 (pt) 2013-09-24 2017-08-01 Giner Inc sistema para tratamento de gás de um implante de célula
CA2926719C (en) 2013-10-08 2020-11-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
AU2015217349A1 (en) 2014-02-11 2016-09-08 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
RS64482B1 (sr) 2014-04-04 2023-09-29 Ai Therapeutics Inc Inhalaciona formulacija rapamicina za lečenje stanja povezanih sa starenjem
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
US12453624B2 (en) 2016-09-19 2025-10-28 Biotronik Ag Polymer-free drug eluting vascular stents
WO2018093956A1 (en) 2016-11-15 2018-05-24 Giner, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
JP7118061B2 (ja) 2016-12-22 2022-08-15 バイオトロニック アクチェンゲゼルシャフト 医療装置のための薬剤放出被膜およびその作製方法
JP7199632B2 (ja) 2017-05-04 2023-01-06 ガイナー，インク． 堅牢なインプラント可能なガス送達装置ならびにそれを含む方法、システムおよび装置
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
FI3898637T3 (fi) 2018-12-18 2025-02-24 Novartis Ag Rapamysiinijohdannaisia
EP3927319A1 (en) 2019-02-20 2021-12-29 AI Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551182A1 (en) * 1992-01-09 1993-07-14 American Home Products Corporation Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid
WO1994009010A1 (en) * 1992-10-09 1994-04-28 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2094858C (en) * 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
ES2146741T3 (es) * 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
RU2158267C2 (ru) * 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551182A1 (en) * 1992-01-09 1993-07-14 American Home Products Corporation Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid
WO1994009010A1 (en) * 1992-10-09 1994-04-28 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Transplantation, 55(6), p 1409, 1993

Also Published As

Publication number Publication date
JP5124431B2 (ja) 2013-01-23
HUP0001267A3 (en) 2002-01-28
US20140187574A1 (en) 2014-07-03
HUP0001267A2 (hu) 2000-11-28
EP0893996B1 (en) 2002-09-18
PT893996E (pt) 2002-12-31
WO1997035575A1 (en) 1997-10-02
CY2404B1 (en) 2004-09-10
US20120177690A1 (en) 2012-07-12
PL328659A1 (en) 1999-02-15
GB9606452D0 (en) 1996-06-05
KR20070083654A (ko) 2007-08-24
ES2184078T3 (es) 2003-04-01
SK132798A3 (en) 1999-03-12
EP0893996A1 (en) 1999-02-03
AU2291897A (en) 1997-10-17
NZ331463A (en) 2001-10-26
ID17195A (id) 1997-12-11
JP2000507226A (ja) 2000-06-13
US20020127248A1 (en) 2002-09-12
MY117798A (en) 2004-08-30
CZ292483B6 (cs) 2003-09-17
US20100152105A1 (en) 2010-06-17
HK1018688A1 (en) 1999-12-30
DE69715611D1 (de) 2002-10-24
NO984340D0 (no) 1998-09-18
PL187732B1 (pl) 2004-09-30
EP1149581A2 (en) 2001-10-31
EP2008657A2 (en) 2008-12-31
CN1214631A (zh) 1999-04-21
EP2008657A3 (en) 2009-02-04
ZA972719B (en) 1998-09-28
IL125812A0 (en) 1999-04-11
EP1149581A3 (en) 2003-12-03
JP2009102349A (ja) 2009-05-14
KR20050038656A (ko) 2005-04-27
ATE224194T1 (de) 2002-10-15
ES2421455T3 (es) 2013-09-02
AU716514B2 (en) 2000-02-24
US6384046B1 (en) 2002-05-07
BR9708358A (pt) 1999-08-03
DE69715611T2 (de) 2003-05-22
IL125812A (en) 2001-12-23
TR199801919T2 (xx) 1999-02-22
CA2247275A1 (en) 1997-10-02
RU2214247C2 (ru) 2003-10-20
CN1124135C (zh) 2003-10-15
HU226422B1 (en) 2008-12-29
DK0893996T3 (da) 2002-12-09
SK284343B6 (sk) 2005-02-04
PT2008657E (pt) 2013-07-12
CA2247275C (en) 2011-10-11
SI2008657T1 (sl) 2013-07-31
CZ307098A3 (cs) 1999-01-13
DK2008657T3 (da) 2013-07-22
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
EP2008657B1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
KR100836971B1 (ko) 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도
JP2009102349A6 (ja) 血管疾病および異種移植におけるラパマイシン誘導体の使用
RU2217136C2 (ru) Новое применение 1,3-пропандиольных производных
AU2003223119A1 (en) Medicament for preventing and/or treating chronic rejection
JP2002541195A (ja) 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物
KR100616020B1 (ko) 맥관장애및이종이식술에서의라파마이신유도체의용도
HK1018688B (en) Use of rapamycin derivatives in vasculopqthies and xenotransplantation
TW550074B (en) Pharmaceutical composition for preventing or treating vasculopathies and chronic rejection
Sinzinger et al. University of Vienna, Garnisongasse 13 A-1090 Vienna, Austria
Perico et al. Altered Renovascular Endothelial Functions During Nephrotoxicity

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20050330

PA0201 Request for examination
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050427

Patent event code: PE09021S01D

PG1501 Laying open of application
AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20061211

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050427

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20070312

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20061211

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080128

Appeal identifier: 2007101002742

Request date: 20070312

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20070411

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20070411

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20070312

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20060927

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20070424

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070312

Effective date: 20080128

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20080128

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20070312

Decision date: 20080128

Appeal identifier: 2007101002742

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20080311

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20080212

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080603

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080603

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110519

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20120518

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130522

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130522

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140521

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140521

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150518

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150518

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160517

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160517

Start annual number: 9

End annual number: 9

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20170926

Termination category: Expiration of duration